NasdaqGS - Nasdaq Real Time Price USD

Pharvaris N.V. (PHVS)

16.56
+0.65
+(4.09%)
At close: May 16 at 4:00:00 PM EDT
16.56
0.00
(0.00%)
After hours: May 16 at 4:00:09 PM EDT
Advanced Chart
Loading Chart for PHVS
  • Previous Close 15.91
  • Open 15.50
  • Bid 16.12 x 100
  • Ask 16.94 x 100
  • Day's Range 15.50 - 16.61
  • 52 Week Range 11.51 - 25.50
  • Volume 40,286
  • Avg. Volume 63,948
  • Market Cap (intraday) 902.406M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -3.14
  • Earnings Date Aug 12, 2025 - Aug 18, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 33.52

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

pharvaris.com

108

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Pharvaris N.V.

Recent News: PHVS

View More
View More

Performance Overview: PHVS

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PHVS
13.62%
S&P 500 (^GSPC)
1.30%

1-Year Return

PHVS
23.72%
S&P 500 (^GSPC)
12.48%

3-Year Return

PHVS
3.21%
S&P 500 (^GSPC)
48.66%

5-Year Return

PHVS
33.76%
S&P 500 (^GSPC)
108.07%

Compare To: PHVS

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

PHVS
Pharvaris N.V.
16.56
+4.09%
Mkt Cap 902.406M
Industry Biotechnology
ABVX
ABIVAX Société Anonyme
6.01
+0.33%
Mkt Cap 381.253M
Industry Biotechnology
ORKA
Oruka Therapeutics, Inc.
10.06
+6.34%
Mkt Cap 376.651M
Industry Biotechnology
KALV
KalVista Pharmaceuticals, Inc.
11.93
+2.32%
Mkt Cap 593.107M
Industry Biotechnology
BSLN.SW
Basilea Pharmaceutica AG
44.25
+1.37%
Mkt Cap CHF 536.46M
Industry Biotechnology
ELOX
Eloxx Pharmaceuticals, Inc.
0.0001
0.00%
Mkt Cap 314
Industry Biotechnology
DNTH
Dianthus Therapeutics, Inc.
19.69
+5.01%
Mkt Cap 633.23M
Industry Biotechnology
FYB.DE
Formycon AG
22.90
0.00%
Mkt Cap EUR 404.515M
Industry Biotechnology
GNFT
Genfit S.A.
4.1900
+5.28%
Mkt Cap 209.484M
Industry Biotechnology
ATXS
Astria Therapeutics, Inc.
3.9600
-0.75%
Mkt Cap 223.479M
Industry Biotechnology
VALN
Valneva SE
6.27
+1.79%
Mkt Cap 524.006M
Industry Biotechnology

Statistics: PHVS

View More

Valuation Measures

Annual
As of 5/16/2025

  • Market Cap

    902.41M

  • Enterprise Value

    638.53M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.58

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -31.88%

  • Return on Equity (ttm)

    -52.20%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -152.54M

  • Diluted EPS (ttm)

    -3.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    236.5M

  • Total Debt/Equity (mrq)

    0.33%

  • Levered Free Cash Flow (ttm)

    -84.15M

View More

Research Analysis: PHVS

View More
View More

Company Insights: PHVS

Research Reports: PHVS

View More
View More

People Also Watch

EWTX Edgewise Therapeutics, Inc.
14.78
+2.28%
 
VOR Vor Biopharma Inc.
0.1769
+3.51%
 
ORIC ORIC Pharmaceuticals, Inc.
4.7300
-0.21%
 
CGEM Cullinan Therapeutics, Inc.
7.50
+3.59%
 
IMCR Immunocore Holdings plc
30.37
+4.51%
 
NUVL Nuvalent, Inc.
73.32
+3.27%
 
PRAX Praxis Precision Medicines, Inc.
37.02
-0.48%
 
DAWN Day One Biopharmaceuticals, Inc.
6.25
+1.46%
 
FDMT 4D Molecular Therapeutics, Inc.
3.4400
+7.50%
 
TYRA Tyra Biosciences, Inc.
9.99
+1.32%
 
OLMA Olema Pharmaceuticals, Inc.
4.7100
+0.43%
 
LVTX LAVA Therapeutics N.V.
1.2500
+0.81%
 
DSGN Design Therapeutics, Inc.
3.5100
+4.46%
 
INZY Inozyme Pharma, Inc.
3.9500
+178.17%
 
CNTA Centessa Pharmaceuticals plc
12.51
-0.64%
 
NBTX Nanobiotix S.A.
3.8600
+1.05%